Parth Rastogi

The clinical management of diabetes mellitus, particularly insulin-deficient phenotypes, represents a complex therapeutic challenge historically defined by lifetime exogenous hormone replacement (AllSci, 2026; Sana Biotechnology, 2026). While the transition to automated insulin delivery pumps and continuous glucose sensors has significantly optimized glycemic profiles, these technological frameworks manage symptoms without addressing the underlying metabolic pathophysiology, while binding...

Introduction In a healthy person, the pancreas performs a quiet, remarkable balancing act every minute of every day. It senses the amount of sugar in the blood and releases just enough insulin to keep those levels in a safe, narrow range — never too high, never too low. For the hundreds of millions of people living with diabetes, that automatic system has broken down. According to the International Diabetes Federation, roughly 589 million adults worldwide now live with diabetes, a number...

Tegoprubart and Islet Cell Transplantation The recent clinical progress of tegoprubart, a targeted monoclonal antibody developed by Eledon Pharmaceuticals, represents a significant paradigm shift in this field. By selectively blocking the CD40 ligand (CD40L) pathway, tegoprubart provides a mechanism to protect transplanted islet cells without the nephrotoxicity and neurotoxicity associated with traditional calcineurin inhibitors, such as tacrolimus. For individuals with type 1 diabetes (T1D),...